Radiosensitizers and Radiochemotherapy in the Treatment of Cancer

Radiosensitizers and Radiochemotherapy in the Treatment of Cancer catalogs and describes the mechanism of action for entities characterized as radiosensitizers. Developments in the biological and physical sciences have introduced new radiosensitizers and defined novel targets for radiosensitization. As a result, a book about radiosensitization must now address a huge range of topics, covering everything from molecular oxygen and high Z elements to monoclonal antibodies and complex phytochemicals. At the molecular level, the understanding of the molecular consequences of DNA damage and the DNA damage response have informed the development of targeted radiosensitizers and shed light on the mode of action of radiochemotherapy protocols of known clinical efficacy. In this book the mechanisms of action at the molecular and cellular level are described for documented radiosensitizers including, where applicable, a brief history of their clinical use and most recent clinical results. In addition, the clinical contex

Shirley Lehnert is currently a professor in the Department of Oncology at McGill University in Montreal, Quebec, Canada. She graduated from London University in the UK with a PhD in biophysics. Dr. Lehnert did postdoctoral work at the University of Rochester. She conducted research in radiobiology and biophysics first at Sloane Kettering Institute and then at the Radiological Research Laboratory of Columbia University in New York. Dr. Lehnert has published extensively in the fields of radiation biology, tumor biology, and drug delivery.